Use of the CRISPR/Cas9 System as a Gene Therapy Mechanism fo

MM
by Meghan McCalla3 views·Updated Jul 6, 2016
Powered by AI

Need to present on this topic?

Create your own polished presentation in minutes. Just describe what you need.

Free to try, no credit card required

Transcript

Discussion:

Background of Current Research

Limitations:

Questions?

Identification of Methyl-CPG-Binding Protein 2 (MeCP2)

Differing Mutations in mice models

MeCP2 is not a global regulator of transcription

Further Research to identify targets of MeCP2

The complex problem of the Rett Syndrome gene mutation

Our Question and Hypothesis

  • Generating mice → time consuming
  • Small group size (only some transgenic mice are viable)
  • Mice don’t have Retts so inducing it won’t be a perfect comparison to humans
  • Although the genetically manipulated mice have features that correlate well with symptoms observed in RTT, no single mouse line is truly mimicking human Rett’s syndrome

Can CRISPR/Cas9 be used successfully to repair the MeCP2 mutation in Rett syndrome-induced mice models?

Hypothesis: Through the use of CRISPR/Cas9 system, the repair of the gene MeCP2 will also lead to correct regulation of its targets, therefore preventing the development of Rett syndrome and all its phenotypic symptoms in mice.

Our Question: Can CRISPR/Cas9 be used successfully to repair the MeCP2 mutation in Rett syndrome-induced mice models?

Complexity of the roles of MeCP2

Implications for human therapeutics

Results showed a successful replacement of mutant MeCP2 with functional MeCP2- CRISPR/Cas9 was successful

Contributions to field of study

Our Rationale

Multiple mutations of MeCP2 can knock-out its function

Countless number of targets of MeCP2

By repairing mutations at MeCP2, regulation will be corrected

Test Question:

Future Directions

The Stages of Retts:

Based off of this experiment, what happens when the CRISPR/Cas9 method is applied to the MeCP2 gene?

a) The mice develop symptoms of Rett syndrome.

b) The mice develop normally and exhibit no Rett syndrome symptoms.

c) The mice have higher anxiety levels.

d) The mice are not able to recognize objects.

Stage 2:

Stage 1:

  • 1-4 years old
  • Communication skills are lost or significantly reduced, rate of head growth slows, disorganized breathing begins as well as characteristic hand movements
  • Acquired microcephaly*
  • Some girls may display autistic-like symptoms
  • Appear after an early period of seemingly typical development
  • 6-8 months, a stagnation of skills becomes apparent, followed by a period of regression
  • Testing on more complex organisms
  • Finding the direct targets of the MeCP2 gene
  • Way to remedy symptoms for potential therapeutics

Stage 4:

Stage 3:

  • Symptoms can last for decades
  • Reduced mobility, curvature of the spine and muscle weakness may occur
  • Can begin at anywhere between 2 & 10 years of age
  • Some worsening of motor problems and seizures may occur

Introduction:

What is Rett's Syndrome?

  • Neurodevelopmenal disorder that affects girls almost exclusively
  • Characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability

Using CRISPR/Cas9 to Repair MeCP2

Using CRISPR/Cas9 to repair MeCP2

Transgenic Mice with Human Mutated MeCP2 Gene

What Causes Rett's?

Current Therapies:

Object Recognition

  • Mutations in the methyl-DNA binding protein MeCP2, found on the X chromosome
  • Phenotype results from misregulation of MeCP2 target genes
  • Two MeCP2 targets:
  • BDNF
  • DLX5

Open Field Test

Mechanisms Behind Retts:

  • MeCP2 mutations were found in 80% of Rett syndrome cases. In these sporadic cases, most mutations occur at CpG mutational hotspots
  • Nearly 70% of the mutations arise from C-T transitions
  • Therapies
  • Physical & Occupational Therapy
  • Speech/Language Therapy
  • Feeding Assistance
  • Physical Assistance
  • Medication
  • Cures
  • No known cures
  • test used to quantify a mouse's recognition of objects in space
  • consists of 5 sessions

1) observation of motility

2-4) 5 small objects placed in an open

field w/the mice

-habituation occurs during these

sessions

5) two of the 5 objects are re-arranged

So What is MeCP2?

  • The MeCP2 gene encodes for the MeCP2 protein
  • This protein is involved in repressing genes & thus prevents them from making proteins when they are not needed
  • When MeCP2 is not functioning propery it no longer represses the correct genes and uneccessary proteins are made
  • Epistatic relationship (gene to gene interaction)
  • This gene contains instructions that are vital for brain development
  • The mutation prevents nerve cells in the brain from functioning properly

Use of the CRISPR/Cas9 System as a Gene Therapy Mechanism for Rett’s Syndrome in a Mouse Model

Anxiety Testing

Anxiety Testing

Elevated Plus Maze (EPM)

Zero Maze

Takeaway Facts:

Why It's Important:

  • Rett syndrome stops you from doing what you want to do, when you want to do it
  • Your body does not obey the commands of your brain
  • Rett syndrome has a ‘spectrum’
  • Symptoms are determined by the location, type and severity of the mutation

- Plus shaped maze with two enclosed arms

and two open arms

- Essentially, the mouse has an aversion towards

the open spaces

- Mouse placed on maze for 5 minutes and

observed for measures of anxiety

Measures of Anxiety:

% of time spent in open arms/entries to open arms

# of entries to each of the arms

- Maze to test measures of anxiety

- Based on same principles as EPM

(aversion to open spaces)

- mice were individually placed on maze and

videotaped for 5 min.

Measures of anxiety:

% time spent freezing

% time spent on open arms

# of transitions between open → closed arms

  • Leading genetic cause of severe disability in females
  • It is as prevalent as cystic fibrosis yet is still relatively unknown outside of the scientific community
  • By restoring MeCP2 we hope to prove that it is possible to recover brain function which will lead to a cure
  • Since Rett syndrome is a neurodevelopmental, NOT a neurodegenerative condition, underlying damage to the brain does not occur
  • Indicates that no gross developmental abnormalities and no neuronal degeneration occurs, but rather small, closely packed neurons with reduced dendritic spines
  • Our thought, it may be possible to completely reverse Retts syndrome

AMIRA

  • Use of stereotactic atlas to determine regional borders program to trace sections
  • Will reassemble traces into 3D images to attain volumetric measures

Behavioral Test

Results

Volumetric Measures

Anxiety Measures Test

  • MeCP2 Repaired mice: more % of time spent on open platforms for both tests

  • Control mice: less % of time spent on open platforms for both tests
  • MeCP2 Repaired mice: less % of time freezing
  • Control mice: more % of time freezing

Behavioral Test

Results

  • Perfusion
  • Mice are anesthetized, perfused with saline, use of PFA
  • Removal of brain
  • Slicing & Mounting
  • Microtome- 50microns thick, every 5th
  • Creysyl violet
  • Mounted on slides scanned on a confocal microscope on to Adobe

Object Recognition Test

References:

*Control mice (with Rett's) had increased anxiety levels*

*MeCP2 Repaired mice had decreased

anxiety levels*

(if inefficient get results

like control.)

  • MeCP2 Repaired mice: increased ability to recognize spatial changes in an open field
  • Control mice: impaired ability to recognize spatial changes in an open field.
  • MeCP2 Repaired mice: able to recognize spatially rearranged objects

  • Control mice: not able to recognize spatially rearranged objects.

Volume Results

*Mice with repaired MeCP2 gene showed improved ability in object recognition ability*

(inefficient, similar results to control).

The amount of time (s) spent in physical contact with the DO (2 objects that have been moved) and NDO (objects that remained constant) is measured in session 5 relative to the amounts of time spent in session 4 for males (A) and females (B).

Amygdala

Hippocampus

  • WT: volume reduction due to impaired object recognition task
  • Experimental: intact brain volume
  • WT: Reduction in volume due to anxious behavior exhibited in elevated plus maze and zero maze
  • Experimental group: Normal brain volume

Calfa, G., Percy, A. K., & Pozzo-Miller, L. (2011). ON

EXPERIMENTAL MODELS OF RETT SYNDROME BASED ON Mecp2

DYSFUNCTION.Experimental Biology and Medicine (Maywood, N.J.), 236(1), 3–19. http://doi.org/10.1258/ebm.2010.010261

Chadwick, Lisa Helbling, and Paul A. Wade. "MeCP2 in Rett

Syndrome: Transcriptional Repressor or Chromatin Architectural Protein?" Current Opinion in Genetics & Development 17.2 (2007): 121-25. Web.

Chahrour, Maria, and Huda Y. Zoghbi. "The Story of Rett

Syndrome: From Clinic to Neurobiology." Neuron 56.3 (2007): 422-37. Web.

Mari, Francesca, et al. "Genetics and Mechanisms of Disease in

Rett Syndrome." Drug Discovery Today: Disease Mechanisms 2.4 (2005): 419-25. Web.

Neul, Jeffrey L., and Huda Y. Zoghbi. "Rett Syndrome: A

Prototypical Neurodevelopmental Disorder." The Neuroscientist Neuroscientist 10.2 (2004): 118-28. Web.

"Quick Learning of CRISPR/Cas9." OriGene Technologies Inc., 7

May 2014. Youtube. Web. 23 Nov. 2015.

Who Did What:

References:

Intro- Meghan

Background -Delanie

Methods - Vivianne, Ghazal, Delanie

Results- Vivianne, Ghazal

Discussion - Delanie, Meghan

Ricceri L, De Filippis B, Laviola G. 2008

Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav Pharmacol. ;19(5–6):501–517.

Squire, L.R., Tecott, L.H., & Nestler, E.J.

2009. Encyclopedia of Neuroscience.

Tao J, Wu H, Sun YE. Deciphering Rett

syndrome with mouse genetics, epigenomics, and human neurons. Int Rev Neurobiol. 2009:89147–89160.

Stearns, N.A, Schaevitz,L.R., Bowling, H.,

Nag, N., Berger, U.B., Berger-Sweeney, J. 2007. Behavioral and anatomical abnormalities in Mecp2 mutant mice: A model for Rett syndrome. Neuroscience, 146 (3), 907-921.